Aardvark Therapeutics moves closer to float with Series C venture round

venture-vc-financing-money-large

Aardvark Therapeutics might not have scored the biggest venture haul in May, but its $85 million Series C round will further strengthen rumors that the California-based company is gearing up for an initial public offering (IPO) this summer, which could come as soon as late July.

Investor interest in what very much looks like a cross-over round has no doubt been sparked by the group’s lead product ARD-101, which has shown it can help blunt the food cravings of Prader-Willi Syndrome patients. While Prader-Willi is a rare genetic disorder, the hope is that ARD-101’s success here can be replicated in the much bigger and more lucrative obesity market.

Last June, Aardvark reported the results of a small 20-patient study showing that ARD-101 had a positive impact on hunger scores in obesity patients. Additionally, the small molecule drug also showed increased weight control compared with placebo, despite the weight loss not being the main focus of the study.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical